Reports Q3 revenue $8.04M, consensus $7.32M. “We have advanced a diverse clinical pipeline of precision medicine oncology therapies targeting biomarker-defined solid tumor populations. Our innovative clinical pipeline has four potential first-in-class clinical programs, including darovasertib (PKC) in a Phase 2/3 potential registrational trial, IDE397 (MAT2A) in Phase 2, IDE161 (PARG) in Phase 1, and GSK101/IDE705 (Pol Theta Helicase) in Phase 1. We also selected a Werner Helicase Development Candidate in collaboration with GSK, for which an IND submission is planned for 2024. These programs represent five potential first-in-class programs, further validating our robust drug discovery platform and enhancing our industry leadership in precision medicine oncology,” said Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IDYA:
- IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
- Ideaya Biosciences 5M share Spot Secondary priced at $23.50
- Ideaya Biosciences $125M Spot Secondary; price range $23.50-$24.50
- Ideaya Biosciences files to sell $125M in common stock and pre-funded warrants
- Ideaya Biosciences price target raised to $36 from $32 at RBC Capital